LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,416,116
تعداد دریافت فایل اصل مقاله11,291,830
Arandi, Nargess, Dehghani, Mehdi. (1401). Immune Microenvironment in Hematologic Malignancies. سامانه مدیریت نشریات علمی, 48(1), 1-3. doi: 10.30476/ijms.2023.48937
Nargess Arandi; Mehdi Dehghani. "Immune Microenvironment in Hematologic Malignancies". سامانه مدیریت نشریات علمی, 48, 1, 1401, 1-3. doi: 10.30476/ijms.2023.48937
Arandi, Nargess, Dehghani, Mehdi. (1401). 'Immune Microenvironment in Hematologic Malignancies', سامانه مدیریت نشریات علمی, 48(1), pp. 1-3. doi: 10.30476/ijms.2023.48937
Arandi, Nargess, Dehghani, Mehdi. Immune Microenvironment in Hematologic Malignancies. سامانه مدیریت نشریات علمی, 1401; 48(1): 1-3. doi: 10.30476/ijms.2023.48937

Immune Microenvironment in Hematologic Malignancies

Iranian Journal of Medical Sciences
مقاله 1، دوره 48، شماره 1، فروردین 2023، صفحه 1-3    اصل مقاله (140.99 K)
نوع مقاله: Editorial
شناسه دیجیتال (DOI): 10.30476/ijms.2023.48937
نویسندگان
Nargess Arandi1؛ Mehdi Dehghani1، 2
1Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Hematology and Medical Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
The role of the tumor microenvironment (TME), especially immune cell compartments, in tumor progression is inevitable and the heterogeneity and complexity of the TME-associated immune cells make it challenging to provide appropriate treatments for hematologic malignancies.
کلیدواژه‌ها
Cytokines؛ Tumor microenvironment؛ Cell survival؛ Lymphoma, T-cell
سایر فایل های مرتبط با مقاله
مراجع
  1. Kawano Y, Roccaro AM, Ghobrial IM, Azzi J. Multiple Myeloma and the Immune Microenvironment. Curr Cancer Drug Targets. 2017;17:806-18. doi: 10.2174/1568009617666170214102301. PubMed PMID: 28201978.
  2. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298-306. doi: 10.1038/nrc3245. PubMed PMID: 22419253.
  3. Garcia-Dominguez DJ, Hontecillas-Prieto L, Palazon-Carrion N, Jimenez-Cortegana C, Sanchez-Margalet V, de la Cruz-Merino L. Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics. Cancers (Basel). 2022;14. doi: 10.3390/cancers14061469. PubMed PMID: 35326620; PubMed Central PMCID: PMCPMC8946119.
  4. Menter T, Tzankov A. Lymphomas and Their Microenvironment: A Multifaceted Relationship. Pathobiology. 2019;86:225-36. doi: 10.1159/000502912. PubMed PMID: 31574515.
  5. Aldinucci D, Gloghini A, Pinto A, Colombatti A, Carbone A. The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leuk Lymphoma. 2012;53:195-201. doi: 10.3109/10428194.2011.605190. PubMed PMID: 21756027.
  6. Cha Z, Qian G, Zang Y, Gu H, Huang Y, Zhu L, et al. Circulating CXCR5+CD4+ T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway. Exp Cell Res. 2017;350:154-60. doi: 10.1016/j.yexcr.2016.11.017. PubMed PMID: 27888017.
  7. Desantis V, Savino FD, Scaringella A, Potenza MA, Nacci C, Frassanito MA, et al. The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. J Clin Med. 2022;11. doi: 10.3390/jcm11092513. PubMed PMID: 35566637; PubMed Central PMCID: PMCPMC9105926.
  8. Benson DM, Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116:2286-94. doi: 10.1182/blood-2010-02-271874. PubMed PMID: 20460501; PubMed Central PMCID: PMCPMC3490105.
  9. Lopes R, Caetano J, Ferreira B, Barahona F, Carneiro EA, Joao C. The Immune Microenvironment in Multiple Myeloma: Friend or Foe? Cancers (Basel). 2021;13. doi: 10.3390/cancers13040625. PubMed PMID: 33562441; PubMed Central PMCID: PMCPMC7914424.
  10. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470-81. doi: 10.1002/cncr.31896. PubMed PMID: 30500073; PubMed Central PMCID: PMCPMC6467779.
  11. Chen Y, Li J, Xu L, Gaman MA, Zou Z. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting. Cell Death Discov. 2022;8:397. doi: 10.1038/s41420-022-01193-0. PubMed PMID: 36163119; PubMed Central PMCID: PMCPMC9513079.
  12. Simioni C, Conti I, Varano G, Brenna C, Costanzi E, Neri LM. The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies. Front Oncol. 2021;11:673506. doi: 10.3389/fonc.2021.673506. PubMed PMID: 34026651; PubMed Central PMCID: PMCPMC8131840.
  13. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011;146:772-84. doi: 10.1016/j.cell.2011.07.033. PubMed PMID: 21871655; PubMed Central PMCID: PMCPMC3387678.
  14. Fu D, Zhang B, Wu S, Zhang Y, Xie J, Ning W, et al. Prognosis and Characterization of Immune Microenvironment in Acute Myeloid Leukemia Through Identification of an Autophagy-Related Signature. Front Immunol. 2021;12:695865. doi: 10.3389/fimmu.2021.695865. PubMed PMID: 34135913; PubMed Central PMCID: PMCPMC8200670.
آمار
تعداد مشاهده مقاله: 1,212
تعداد دریافت فایل اصل مقاله: 938


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب